Pharmacovigilance Market ? Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Clinical Trial Phase (Pre-Clinical, Phase 1, Phase 2, Phase 3, and Phase 4), By Method (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining), By Service Provider (In-House, Contract Outsourcing), By Process Flow (Case Data Management, Signal Detection, Risk Management System), By Therapeutic Area (Oncology, Neurology, Cardiology, Others), By End-User (Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Others), By Region & Competition, 2021-2031F
The Global Pharmacovigilance Market is projected to experience substantial growth, rising from USD 8.21 Billion in 2025 to USD 15.37 Billion by 2031, reflecting a compound annual growth rate of 11.02%. Defined as the scientific discipline focused on detecting, assessing, understanding, and preventing adverse effects or medicine-related issues, the market is primarily driven by increasing global pharmaceutical consumption and the growing prevalence of chronic diseases that require long-term medication. Additionally, stringent regulatory requirements enforced by health authorities worldwide mandate that pharmaceutical companies maintain rigorous safety surveillance systems, serving as a fundamental driver for the industry's expansion.
Despite these growth prospects, the market faces a significant hurdle due to the high costs and complexity involved in managing the rapidly increasing volume of safety data. This surge in data places immense pressure on existing resources and necessitates the development of robust infrastructure. For instance, the European Medicines Agency reported that in 2024, over 1.7 million adverse drug reaction reports were submitted to EudraVigilance, underscoring the massive scale of information that organizations must accurately capture and analyze to ensure regulatory compliance.
Market Driver
The escalating prevalence of chronic diseases and the resulting increase in medication consumption serve as key catalysts for the Global Pharmacovigilance Market. As the global burden of conditions like oncology, diabetes, and cardiovascular disorders rises, the volume of administered drugs increases, necessitating strict monitoring for adverse events. Highlighting this trend, the World Health Organization's 'Global Status Report on Cancer 2024', released in February 2024, estimated there were 20 million new cancer cases in 2022, indicating a growing patient population that requires long-term pharmacological treatment. This rise in disease incidence compels pharmaceutical entities to expand their pharmacovigilance operations to effectively track the safety profiles of complex therapies used in chronic care.
Furthermore, the expansion of clinical trials and drug research and development accelerates market growth by generating vast amounts of safety data that must be processed before authorization. Pharmaceutical companies are investing heavily in innovation to meet unmet medical needs, heightening the demand for surveillance during both clinical and post-marketing phases. According to the European Federation of Pharmaceutical Industries and Associations' June 2024 report, 'The Pharmaceutical Industry in Figures 2024', R&D expenditure in Europe was projected to reach ?50,000 million in 2023. To manage the regulatory oversight associated with this investment, agencies are also enhancing their capabilities; the US Food and Drug Administration requested a budget of $7.2 billion for fiscal year 2025 in 2024 to strengthen safety programs and public health infrastructure.
Market Challenge
The rapid increase in safety data volume poses a significant barrier to the Global Pharmacovigilance Market's expansion. As adverse event reports multiply exponentially, pharmaceutical companies are forced to divert substantial capital toward maintaining basic compliance rather than investing in innovation. The complexity and high expense of validating and processing this influx create a severe financial strain, particularly for small and medium-sized enterprises. These smaller entities often lack the budgetary flexibility to absorb the soaring operational costs required for rigorous safety surveillance, effectively limiting their participation in the market and hampering overall industry growth.
This resource-intensive environment is further exacerbated by the sheer scale of information that must be managed to avoid regulatory penalties. The relentless acceleration of data intake compels organizations to prioritize immediate processing capabilities over long-term strategic development. According to the Uppsala Monitoring Centre, the global VigiBase system received an average of approximately 50,000 new individual case safety reports per week in 2024. This magnitude of data influx highlights the immense pressure on industry stakeholders, who must continuously expand their infrastructure solely to keep pace with reporting requirements, thereby stifling broader market opportunities and profitability.
Market Trends
The integration of Artificial Intelligence and Machine Learning is fundamentally reshaping the Global Pharmacovigilance Market by shifting safety operations from reactive compliance to proactive risk management. Facing an exponential rise in adverse event reports, pharmaceutical companies are increasingly utilizing predictive algorithms and natural language processing to automate labor-intensive tasks such as case intake, validity checks, and narrative generation. This technological advancement allows safety teams to focus on complex benefit-risk assessments rather than manual data entry, improving the speed and accuracy of signal detection. According to the Pistoia Alliance's 'Lab of the Future 2025 Report' from September 2025, 60% of respondents identified AI and machine learning as their top technology investment for the next two years, underscoring the sector's commitment to digital transformation.
Simultaneously, strategic outsourcing to Contract Research Organizations (CROs) has emerged as a dominant trend, driven by the need to navigate complex regulatory landscapes and manage fluctuating resource demands without incurring fixed overheads. Small and medium-sized enterprises, in particular, are leveraging the specialized infrastructure of CROs to ensure global compliance and scalability, effectively converting fixed operational costs into variable expenses. This reliance on external partners enables bio-pharmaceutical firms to access advanced vigilance platforms and global safety networks that would be prohibitively expensive to build in-house. As reported by the Association of Clinical Research Organizations in July 2025, member companies generated an estimated $98 billion in revenue in 2024, reflecting the substantial scale of operations now entrusted to third-party providers.
Key Market Players
In this report, the Global Pharmacovigilance Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Pharmacovigilance Market.
Available Customizations:
Global Pharmacovigilance Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Despite these growth prospects, the market faces a significant hurdle due to the high costs and complexity involved in managing the rapidly increasing volume of safety data. This surge in data places immense pressure on existing resources and necessitates the development of robust infrastructure. For instance, the European Medicines Agency reported that in 2024, over 1.7 million adverse drug reaction reports were submitted to EudraVigilance, underscoring the massive scale of information that organizations must accurately capture and analyze to ensure regulatory compliance.
Market Driver
The escalating prevalence of chronic diseases and the resulting increase in medication consumption serve as key catalysts for the Global Pharmacovigilance Market. As the global burden of conditions like oncology, diabetes, and cardiovascular disorders rises, the volume of administered drugs increases, necessitating strict monitoring for adverse events. Highlighting this trend, the World Health Organization's 'Global Status Report on Cancer 2024', released in February 2024, estimated there were 20 million new cancer cases in 2022, indicating a growing patient population that requires long-term pharmacological treatment. This rise in disease incidence compels pharmaceutical entities to expand their pharmacovigilance operations to effectively track the safety profiles of complex therapies used in chronic care.
Furthermore, the expansion of clinical trials and drug research and development accelerates market growth by generating vast amounts of safety data that must be processed before authorization. Pharmaceutical companies are investing heavily in innovation to meet unmet medical needs, heightening the demand for surveillance during both clinical and post-marketing phases. According to the European Federation of Pharmaceutical Industries and Associations' June 2024 report, 'The Pharmaceutical Industry in Figures 2024', R&D expenditure in Europe was projected to reach ?50,000 million in 2023. To manage the regulatory oversight associated with this investment, agencies are also enhancing their capabilities; the US Food and Drug Administration requested a budget of $7.2 billion for fiscal year 2025 in 2024 to strengthen safety programs and public health infrastructure.
Market Challenge
The rapid increase in safety data volume poses a significant barrier to the Global Pharmacovigilance Market's expansion. As adverse event reports multiply exponentially, pharmaceutical companies are forced to divert substantial capital toward maintaining basic compliance rather than investing in innovation. The complexity and high expense of validating and processing this influx create a severe financial strain, particularly for small and medium-sized enterprises. These smaller entities often lack the budgetary flexibility to absorb the soaring operational costs required for rigorous safety surveillance, effectively limiting their participation in the market and hampering overall industry growth.
This resource-intensive environment is further exacerbated by the sheer scale of information that must be managed to avoid regulatory penalties. The relentless acceleration of data intake compels organizations to prioritize immediate processing capabilities over long-term strategic development. According to the Uppsala Monitoring Centre, the global VigiBase system received an average of approximately 50,000 new individual case safety reports per week in 2024. This magnitude of data influx highlights the immense pressure on industry stakeholders, who must continuously expand their infrastructure solely to keep pace with reporting requirements, thereby stifling broader market opportunities and profitability.
Market Trends
The integration of Artificial Intelligence and Machine Learning is fundamentally reshaping the Global Pharmacovigilance Market by shifting safety operations from reactive compliance to proactive risk management. Facing an exponential rise in adverse event reports, pharmaceutical companies are increasingly utilizing predictive algorithms and natural language processing to automate labor-intensive tasks such as case intake, validity checks, and narrative generation. This technological advancement allows safety teams to focus on complex benefit-risk assessments rather than manual data entry, improving the speed and accuracy of signal detection. According to the Pistoia Alliance's 'Lab of the Future 2025 Report' from September 2025, 60% of respondents identified AI and machine learning as their top technology investment for the next two years, underscoring the sector's commitment to digital transformation.
Simultaneously, strategic outsourcing to Contract Research Organizations (CROs) has emerged as a dominant trend, driven by the need to navigate complex regulatory landscapes and manage fluctuating resource demands without incurring fixed overheads. Small and medium-sized enterprises, in particular, are leveraging the specialized infrastructure of CROs to ensure global compliance and scalability, effectively converting fixed operational costs into variable expenses. This reliance on external partners enables bio-pharmaceutical firms to access advanced vigilance platforms and global safety networks that would be prohibitively expensive to build in-house. As reported by the Association of Clinical Research Organizations in July 2025, member companies generated an estimated $98 billion in revenue in 2024, reflecting the substantial scale of operations now entrusted to third-party providers.
Key Market Players
- IQVIA Inc.
- ArisGlobal
- Parexel International Corporation
- Labcorp Drug Development
- Accenture
- Cognizant Technology Solutions
- Ergomed Group
- ICON plc
- Syneos Health
- Wipro Limited
In this report, the Global Pharmacovigilance Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Pharmacovigilance Market, By Clinical Trial Phase
- Pre-Clinical
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Pharmacovigilance Market, By Method
- Spontaneous Reporting
- Intensified ADR Reporting
- Targeted Spontaneous Reporting
- Cohort Event Monitoring
- EHR Mining
- Pharmacovigilance Market, By Service Provider
- In-House
- Contract Outsourcing
- Pharmacovigilance Market, By Process Flow
- Case Data Management
- Signal Detection
- Risk Management System
- Pharmacovigilance Market, By Therapeutic Area
- Oncology
- Neurology
- Cardiology
- Others
- Pharmacovigilance Market, By End-User
- Pharmaceutical & Biotechnology Companies
- Medical Device Manufacturers
- Others
- Pharmacovigilance Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Pharmacovigilance Market.
Available Customizations:
Global Pharmacovigilance Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL PHARMACOVIGILANCE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Clinical Trial Phase (Pre-Clinical, Phase 1, Phase 2, Phase 3, Phase 4)
5.2.2. By Method (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining)
5.2.3. By Service Provider (In-House, Contract Outsourcing)
5.2.4. By Process Flow (Case Data Management, Signal Detection, Risk Management System)
5.2.5. By Therapeutic Area (Oncology, Neurology, Cardiology, Others)
5.2.6. By End-User (Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Others)
5.2.7. By Region
5.2.8. By Company (2025)
5.3. Market Map
6. NORTH AMERICA PHARMACOVIGILANCE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Clinical Trial Phase
6.2.2. By Method
6.2.3. By Service Provider
6.2.4. By Process Flow
6.2.5. By Therapeutic Area
6.2.6. By End-User
6.2.7. By Country
6.3. North America: Country Analysis
6.3.1. United States Pharmacovigilance Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Clinical Trial Phase
6.3.1.2.2. By Method
6.3.1.2.3. By Service Provider
6.3.1.2.4. By Process Flow
6.3.1.2.5. By Therapeutic Area
6.3.1.2.6. By End-User
6.3.2. Canada Pharmacovigilance Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Clinical Trial Phase
6.3.2.2.2. By Method
6.3.2.2.3. By Service Provider
6.3.2.2.4. By Process Flow
6.3.2.2.5. By Therapeutic Area
6.3.2.2.6. By End-User
6.3.3. Mexico Pharmacovigilance Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Clinical Trial Phase
6.3.3.2.2. By Method
6.3.3.2.3. By Service Provider
6.3.3.2.4. By Process Flow
6.3.3.2.5. By Therapeutic Area
6.3.3.2.6. By End-User
7. EUROPE PHARMACOVIGILANCE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Clinical Trial Phase
7.2.2. By Method
7.2.3. By Service Provider
7.2.4. By Process Flow
7.2.5. By Therapeutic Area
7.2.6. By End-User
7.2.7. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Pharmacovigilance Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Clinical Trial Phase
7.3.1.2.2. By Method
7.3.1.2.3. By Service Provider
7.3.1.2.4. By Process Flow
7.3.1.2.5. By Therapeutic Area
7.3.1.2.6. By End-User
7.3.2. France Pharmacovigilance Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Clinical Trial Phase
7.3.2.2.2. By Method
7.3.2.2.3. By Service Provider
7.3.2.2.4. By Process Flow
7.3.2.2.5. By Therapeutic Area
7.3.2.2.6. By End-User
7.3.3. United Kingdom Pharmacovigilance Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Clinical Trial Phase
7.3.3.2.2. By Method
7.3.3.2.3. By Service Provider
7.3.3.2.4. By Process Flow
7.3.3.2.5. By Therapeutic Area
7.3.3.2.6. By End-User
7.3.4. Italy Pharmacovigilance Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Clinical Trial Phase
7.3.4.2.2. By Method
7.3.4.2.3. By Service Provider
7.3.4.2.4. By Process Flow
7.3.4.2.5. By Therapeutic Area
7.3.4.2.6. By End-User
7.3.5. Spain Pharmacovigilance Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Clinical Trial Phase
7.3.5.2.2. By Method
7.3.5.2.3. By Service Provider
7.3.5.2.4. By Process Flow
7.3.5.2.5. By Therapeutic Area
7.3.5.2.6. By End-User
8. ASIA PACIFIC PHARMACOVIGILANCE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Clinical Trial Phase
8.2.2. By Method
8.2.3. By Service Provider
8.2.4. By Process Flow
8.2.5. By Therapeutic Area
8.2.6. By End-User
8.2.7. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Pharmacovigilance Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Clinical Trial Phase
8.3.1.2.2. By Method
8.3.1.2.3. By Service Provider
8.3.1.2.4. By Process Flow
8.3.1.2.5. By Therapeutic Area
8.3.1.2.6. By End-User
8.3.2. India Pharmacovigilance Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Clinical Trial Phase
8.3.2.2.2. By Method
8.3.2.2.3. By Service Provider
8.3.2.2.4. By Process Flow
8.3.2.2.5. By Therapeutic Area
8.3.2.2.6. By End-User
8.3.3. Japan Pharmacovigilance Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Clinical Trial Phase
8.3.3.2.2. By Method
8.3.3.2.3. By Service Provider
8.3.3.2.4. By Process Flow
8.3.3.2.5. By Therapeutic Area
8.3.3.2.6. By End-User
8.3.4. South Korea Pharmacovigilance Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Clinical Trial Phase
8.3.4.2.2. By Method
8.3.4.2.3. By Service Provider
8.3.4.2.4. By Process Flow
8.3.4.2.5. By Therapeutic Area
8.3.4.2.6. By End-User
8.3.5. Australia Pharmacovigilance Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Clinical Trial Phase
8.3.5.2.2. By Method
8.3.5.2.3. By Service Provider
8.3.5.2.4. By Process Flow
8.3.5.2.5. By Therapeutic Area
8.3.5.2.6. By End-User
9. MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Clinical Trial Phase
9.2.2. By Method
9.2.3. By Service Provider
9.2.4. By Process Flow
9.2.5. By Therapeutic Area
9.2.6. By End-User
9.2.7. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Pharmacovigilance Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Clinical Trial Phase
9.3.1.2.2. By Method
9.3.1.2.3. By Service Provider
9.3.1.2.4. By Process Flow
9.3.1.2.5. By Therapeutic Area
9.3.1.2.6. By End-User
9.3.2. UAE Pharmacovigilance Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Clinical Trial Phase
9.3.2.2.2. By Method
9.3.2.2.3. By Service Provider
9.3.2.2.4. By Process Flow
9.3.2.2.5. By Therapeutic Area
9.3.2.2.6. By End-User
9.3.3. South Africa Pharmacovigilance Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Clinical Trial Phase
9.3.3.2.2. By Method
9.3.3.2.3. By Service Provider
9.3.3.2.4. By Process Flow
9.3.3.2.5. By Therapeutic Area
9.3.3.2.6. By End-User
10. SOUTH AMERICA PHARMACOVIGILANCE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Clinical Trial Phase
10.2.2. By Method
10.2.3. By Service Provider
10.2.4. By Process Flow
10.2.5. By Therapeutic Area
10.2.6. By End-User
10.2.7. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Pharmacovigilance Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Clinical Trial Phase
10.3.1.2.2. By Method
10.3.1.2.3. By Service Provider
10.3.1.2.4. By Process Flow
10.3.1.2.5. By Therapeutic Area
10.3.1.2.6. By End-User
10.3.2. Colombia Pharmacovigilance Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Clinical Trial Phase
10.3.2.2.2. By Method
10.3.2.2.3. By Service Provider
10.3.2.2.4. By Process Flow
10.3.2.2.5. By Therapeutic Area
10.3.2.2.6. By End-User
10.3.3. Argentina Pharmacovigilance Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Clinical Trial Phase
10.3.3.2.2. By Method
10.3.3.2.3. By Service Provider
10.3.3.2.4. By Process Flow
10.3.3.2.5. By Therapeutic Area
10.3.3.2.6. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL PHARMACOVIGILANCE MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. IQVIA Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. ArisGlobal
15.3. Parexel International Corporation
15.4. Labcorp Drug Development
15.5. Accenture
15.6. Cognizant Technology Solutions
15.7. Ergomed Group
15.8. ICON plc
15.9. Syneos Health
15.10. Wipro Limited
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL PHARMACOVIGILANCE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Clinical Trial Phase (Pre-Clinical, Phase 1, Phase 2, Phase 3, Phase 4)
5.2.2. By Method (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining)
5.2.3. By Service Provider (In-House, Contract Outsourcing)
5.2.4. By Process Flow (Case Data Management, Signal Detection, Risk Management System)
5.2.5. By Therapeutic Area (Oncology, Neurology, Cardiology, Others)
5.2.6. By End-User (Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Others)
5.2.7. By Region
5.2.8. By Company (2025)
5.3. Market Map
6. NORTH AMERICA PHARMACOVIGILANCE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Clinical Trial Phase
6.2.2. By Method
6.2.3. By Service Provider
6.2.4. By Process Flow
6.2.5. By Therapeutic Area
6.2.6. By End-User
6.2.7. By Country
6.3. North America: Country Analysis
6.3.1. United States Pharmacovigilance Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Clinical Trial Phase
6.3.1.2.2. By Method
6.3.1.2.3. By Service Provider
6.3.1.2.4. By Process Flow
6.3.1.2.5. By Therapeutic Area
6.3.1.2.6. By End-User
6.3.2. Canada Pharmacovigilance Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Clinical Trial Phase
6.3.2.2.2. By Method
6.3.2.2.3. By Service Provider
6.3.2.2.4. By Process Flow
6.3.2.2.5. By Therapeutic Area
6.3.2.2.6. By End-User
6.3.3. Mexico Pharmacovigilance Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Clinical Trial Phase
6.3.3.2.2. By Method
6.3.3.2.3. By Service Provider
6.3.3.2.4. By Process Flow
6.3.3.2.5. By Therapeutic Area
6.3.3.2.6. By End-User
7. EUROPE PHARMACOVIGILANCE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Clinical Trial Phase
7.2.2. By Method
7.2.3. By Service Provider
7.2.4. By Process Flow
7.2.5. By Therapeutic Area
7.2.6. By End-User
7.2.7. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Pharmacovigilance Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Clinical Trial Phase
7.3.1.2.2. By Method
7.3.1.2.3. By Service Provider
7.3.1.2.4. By Process Flow
7.3.1.2.5. By Therapeutic Area
7.3.1.2.6. By End-User
7.3.2. France Pharmacovigilance Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Clinical Trial Phase
7.3.2.2.2. By Method
7.3.2.2.3. By Service Provider
7.3.2.2.4. By Process Flow
7.3.2.2.5. By Therapeutic Area
7.3.2.2.6. By End-User
7.3.3. United Kingdom Pharmacovigilance Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Clinical Trial Phase
7.3.3.2.2. By Method
7.3.3.2.3. By Service Provider
7.3.3.2.4. By Process Flow
7.3.3.2.5. By Therapeutic Area
7.3.3.2.6. By End-User
7.3.4. Italy Pharmacovigilance Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Clinical Trial Phase
7.3.4.2.2. By Method
7.3.4.2.3. By Service Provider
7.3.4.2.4. By Process Flow
7.3.4.2.5. By Therapeutic Area
7.3.4.2.6. By End-User
7.3.5. Spain Pharmacovigilance Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Clinical Trial Phase
7.3.5.2.2. By Method
7.3.5.2.3. By Service Provider
7.3.5.2.4. By Process Flow
7.3.5.2.5. By Therapeutic Area
7.3.5.2.6. By End-User
8. ASIA PACIFIC PHARMACOVIGILANCE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Clinical Trial Phase
8.2.2. By Method
8.2.3. By Service Provider
8.2.4. By Process Flow
8.2.5. By Therapeutic Area
8.2.6. By End-User
8.2.7. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Pharmacovigilance Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Clinical Trial Phase
8.3.1.2.2. By Method
8.3.1.2.3. By Service Provider
8.3.1.2.4. By Process Flow
8.3.1.2.5. By Therapeutic Area
8.3.1.2.6. By End-User
8.3.2. India Pharmacovigilance Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Clinical Trial Phase
8.3.2.2.2. By Method
8.3.2.2.3. By Service Provider
8.3.2.2.4. By Process Flow
8.3.2.2.5. By Therapeutic Area
8.3.2.2.6. By End-User
8.3.3. Japan Pharmacovigilance Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Clinical Trial Phase
8.3.3.2.2. By Method
8.3.3.2.3. By Service Provider
8.3.3.2.4. By Process Flow
8.3.3.2.5. By Therapeutic Area
8.3.3.2.6. By End-User
8.3.4. South Korea Pharmacovigilance Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Clinical Trial Phase
8.3.4.2.2. By Method
8.3.4.2.3. By Service Provider
8.3.4.2.4. By Process Flow
8.3.4.2.5. By Therapeutic Area
8.3.4.2.6. By End-User
8.3.5. Australia Pharmacovigilance Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Clinical Trial Phase
8.3.5.2.2. By Method
8.3.5.2.3. By Service Provider
8.3.5.2.4. By Process Flow
8.3.5.2.5. By Therapeutic Area
8.3.5.2.6. By End-User
9. MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Clinical Trial Phase
9.2.2. By Method
9.2.3. By Service Provider
9.2.4. By Process Flow
9.2.5. By Therapeutic Area
9.2.6. By End-User
9.2.7. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Pharmacovigilance Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Clinical Trial Phase
9.3.1.2.2. By Method
9.3.1.2.3. By Service Provider
9.3.1.2.4. By Process Flow
9.3.1.2.5. By Therapeutic Area
9.3.1.2.6. By End-User
9.3.2. UAE Pharmacovigilance Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Clinical Trial Phase
9.3.2.2.2. By Method
9.3.2.2.3. By Service Provider
9.3.2.2.4. By Process Flow
9.3.2.2.5. By Therapeutic Area
9.3.2.2.6. By End-User
9.3.3. South Africa Pharmacovigilance Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Clinical Trial Phase
9.3.3.2.2. By Method
9.3.3.2.3. By Service Provider
9.3.3.2.4. By Process Flow
9.3.3.2.5. By Therapeutic Area
9.3.3.2.6. By End-User
10. SOUTH AMERICA PHARMACOVIGILANCE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Clinical Trial Phase
10.2.2. By Method
10.2.3. By Service Provider
10.2.4. By Process Flow
10.2.5. By Therapeutic Area
10.2.6. By End-User
10.2.7. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Pharmacovigilance Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Clinical Trial Phase
10.3.1.2.2. By Method
10.3.1.2.3. By Service Provider
10.3.1.2.4. By Process Flow
10.3.1.2.5. By Therapeutic Area
10.3.1.2.6. By End-User
10.3.2. Colombia Pharmacovigilance Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Clinical Trial Phase
10.3.2.2.2. By Method
10.3.2.2.3. By Service Provider
10.3.2.2.4. By Process Flow
10.3.2.2.5. By Therapeutic Area
10.3.2.2.6. By End-User
10.3.3. Argentina Pharmacovigilance Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Clinical Trial Phase
10.3.3.2.2. By Method
10.3.3.2.3. By Service Provider
10.3.3.2.4. By Process Flow
10.3.3.2.5. By Therapeutic Area
10.3.3.2.6. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL PHARMACOVIGILANCE MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. IQVIA Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. ArisGlobal
15.3. Parexel International Corporation
15.4. Labcorp Drug Development
15.5. Accenture
15.6. Cognizant Technology Solutions
15.7. Ergomed Group
15.8. ICON plc
15.9. Syneos Health
15.10. Wipro Limited
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
